Healthcare Industry News:  Terumo  

Devices Cardiology Personnel

 News Release - November 24, 2008

Terumo Heart Announces Appointment of William Pinon to Chief Executive Officer and President

ANN ARBOR, Mich., Nov. 24 -- (Healthcare Sales & Marketing Network) -- Terumo Heart, Inc. is pleased to announce the appointment of William Pinon to the position of Chief Executive Officer (C.E.O.) and President, effective immediately. "With its innovative mag-lev technology, Terumo Heart is positioned for a strong leadership role in the future treatment of heart failure. I am excited to lead the acceleration of enrollment in the DuraHeart U.S. Pivotal trials in up to 40 clinical sites, and further capitalize on the commercial potential for DuraHeart's CE Mark in Europe," Mr. Pinon commented. Chisato Nojiri, M.D. Ph.D. will continue to serve as Chairperson of the Board and Chief Medical Officer of Terumo Heart, Inc. Dr. Nojiri has been instrumental in bringing the product from its very early development phase through commercialization in Europe, to the start of the U.S. Pivotal Clinical Trial and recent completion of the Japanese Clinical Trial patient enrollment. Dr. Nojiri will continue her global clinical and scientific focus and leadership.

"With the expansion of our U.S. clinical sites, Terumo Heart is experiencing rapid growth. Mr. Pinon's proven track record in the cardiovascular industry and extensive sales and operational experience, are ideally suited to lead our commercialization efforts in the U.S. and continued growth in Europe," said Dr. Nojiri.

Most recently, Mr. Pinon was C.E.O. of Bioheart, a biotechnology company focused on the development of heart failure therapies and devices. Prior to Bioheart, Mr. Pinon held a variety of positions with Johnson & Johnson including Worldwide Vice President of Sales and Marketing at Cordis Corporation where he oversaw the cardiovascular business including the market leading drug eluting stent, CYPHER (TM). Mr. Pinon received a bachelor's degree in biology from the University of Oregon.

Terumo Heart, Inc. is a U.S. subsidiary of Terumo Corporation with headquarters and manufacturing facilities in Ann Arbor, Michigan. The company's focus is the innovation and introduction of products to improve the quality of healthcare for heart failure patients. Terumo Corporation, located in Tokyo, Japan, is a leading developer, manufacturer and global marketer of a wide array of medical products. DuraHeart is limited to investigational use only in the United States, and is CE marked in Europe.


Source: Terumo Heart

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.